We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Plans to Resume Bulk Varicella Production Soon
Merck Plans to Resume Bulk Varicella Production Soon
August 6, 2007
As Merck corrects a manufacturing error that resulted in subpotent varicella bulk ingredient for its combination measles, mumps, rubella (MMR) and chickenpox (varicella) vaccine ProQuad, the company anticipates resuming production of the bulk ingredient shortly, Merck CEO Dick Clark said during the firm’s earnings call last month.